^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
03/10/2021
Excerpt:
Australian prescription medicine decision summary...Ruxience (rituximab) was approved for the following therapeutic use...Non-Hodgkin's lymphoma...CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/26/2020
Excerpt:
RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with...Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
Secondary therapy:
CHOP; Chemotherapy
Evidence Level:
Sensitive: A1 - Approval
Published date:
04/01/2020
Excerpt:
Ruxience is indicated for the treatment of patients with CD20 positive diffuse large B cell non‑Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Secondary therapy:
CHOP